Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma

Authors

S. Patel
M. von Mehren
D. R. Reed
P. Kaiser
J. Charlson
C. W. Ryan
D. Rushing
M. Livingston
R. G. Maki, Zucker School of Medicine at Hofstra/Northwell
G. D. Demetri
+10 additional authors

Publication Date

2019

Journal Title

Cancer

Volume Number

125

Issue Number

15

Pages

2610 - 2620

Document Type

Article

Status

Faculty

Facility

School of Medicine

Primary Department

Hematology/Medical Oncology

PMID

31173362

DOI

10.1002/cncr.32117